Democratize access to gene therapy investment, offering micro-investment opportunities (similar to platforms like Acorns or Stash) focused on cancer gene-editing companies. Allows average citizens to benefit financially from the growth of this exclusive treatment option, even if they cannot directly afford it. Funds would be ethically screened to avoid investment in companies with exploitative pricing practices.